Videos

Alexander Drilon, MD, discusses what to know when testing for NTRK gene fusions in patients with lung cancer.

Bruno Bockorny, MD, discusses the findings from a study of botensilimab plus bastilimab for the treatment of patients with recurrent platinum refractory/resistant ovarian cancer.

Edwin Choy, MD, discusses the evolution of treatment for gastrointestinal stromal tumors, including surgery and targeted therapy.

Sumanta “Monty” K. Pal, MD, FASCO, discuss exciting data in the renal cell carcinoma space.

Monty Pal, MD discusses the implications of updated NCCN guidelines on mRCC treatment selection and sequencing in 2023 as well as unmet needs in the mRCC treatment landscape.

A closer look at lenvatinib plus everolimus in patients with advanced renal cell carcinoma, touching on dose-related toxicities.

Thoughtful discussion of study data supporting the use of tivozanib in patients with metastatic renal cell carcinoma, in the relapsed/refractory setting.

Dr. Pal discusses clinical insights concerning treatment selection and sequencing in patients with metastatic renal cell carcinoma.

Monty Pal, MD, introduces a metastatic clear cell renal cell carcinoma (ccRCC) patient case and shares how he may approach treatment.

John Diaz, MD, discusses some of the challenges with using targeted therapies in the ovarian cancer space.

Michael Tees, MD, discusses the preliminary safety outcomes observed for an allogeneic chimeric antigen receptor T-cell therapy for large B-cell lymphoma.

Looking at the results of study assessing performing blood-based host immune classifier proteomic testing in patients with non–small cell lung cancer shows the potential for predicting the success of immunotherapy based on a patient’s biomarkers.

Pedro C. Barata, MD, MSc, discusses research topics to help bring more precision medicine options to the prostate cancer landscape.

Shared perspectives on the frontline use of brigatinib therapy in ALK+ NSCLC and results from the ALTA-1L clinical trial.

Centering discussion on clinical trial data in ALK+ NSCLC, panelists highlight the frontline use of alectinib in the ALEX study.

Gene G. Finley, MD, provides advice to community oncologists who are treating patients with small cell lung cancer.

Laura A. Dawson, MD, FRCPC, discusses the NRG/RTOG 1112 study for patients with hepatocellular carcinoma which evaluated stereotactic body radiation therapy followed by sorafenib compared with sorafenib alone.

Dr Bose engages with emergent trial data presented at the American Society of Hematology (ASH) 2022 Annual Meeting.

Prithviraj Bose, MD discusses typical patient outcomes in PV and other myeloproliferative neoplasms, emphasizing the importance of patient priorities and symptom management.

A practical approach to patient monitoring, with a focus on assessing treatment efficacy and individualized patient care.

A review of available treatments, treatment selection, and treatment sequencing for patients with PV as informed by clinical trial data.

Subject matter expert reviews biological mechanisms underpinning myeloproliferative neoplasms and standard-of-care risk assessment for patients with PV.

Closing out her discussion on the treatment and management of HR+/HER2- mBC, Hope Rugo, MD, FASCO, highlights unmet needs and future directions in the field.

Dr Hope Rugo shares insight on how she approaches second-line and higher treatment selection in patients with HR+/HER2- metastatic breast cancer who experience disease progression on first-line therapy.

Centering discussion on the EMERALD trial, Dr Hope Rugo, reflects on the safety and efficacy of elacestrant in patients with HR+/HER2- mBC.

A comprehensive review of treatment options for patients with HR+/HER2- metastatic breast cancer who experience disease progression on standard-of-care therapies such as combination CDK4/6 and aromatase inhibitors.

Expert perspective on the role of ESR1 mutations in HR+/HER2- mBC and best practices on biomarker testing for patients experiencing disease progression on endocrine therapy.

Expert oncologist Hope Rugo, MD, FASCO, reviews the diagnosis and treatment of a 57-year-old woman with HR+/HER2- metastatic breast cancer (mBC).

Patrick Wen, MD, looks at how emerging evidence has shown promise for targeting mutations in patients with glioblastomas when it was once believed these therapies may not work for these patients.

Dr Bose shares his initial impressions of a PV patient case before discussing typical patient presentation and criteria for PV diagnosis.